In FY24, a Mumbai hair-loss brand that most Indians had never heard of turned its first profit — about ₹9 crore on ₹236 crore (about $25 million; $1 ≈ ₹96.0, Trading Economics, 18 September 2026) of revenue, after nearly quadrupling sales in a single year. A year later it deliberately handed that profit back, slipping to a roughly ₹23 crore loss in FY25 even as revenue climbed again to ₹338 crore.
That is the tension at the centre of Traya, the doctor-led hair-health brand run by Tatvartha Health Private Limited. It does not really sell shampoo. It sells a diagnosis, a five-to-six-month plan and a coach who calls to check whether you took your pills — and it spends heavily to convince strangers that hair fall is a medical problem, not a cosmetic one. This deep dive works through the numbers on both sides of that bet, using the company’s Registrar of Companies (RoC) filings as reported by Entrackr and Inc42, and separates what is documented from what is merely claimed.
Quick facts
| Company | Traya (legal entity: Tatvartha Health Private Limited; CIN U85300GJ2019PTC107353) |
| Founded | Entity incorporated 29 March 2019 (RoC Ahmedabad); brand launched May 2019, Mumbai |
| Founder(s) | Saloni Anand and Altaf Saiyed (co-founders, married couple); Mansuk Lala, a pharma-industry veteran, is CEO and is listed as a co-founder in company databases |
| Businesses | Doctor-led D2C hair-loss treatment: personalised plans combining Ayurveda, dermatology and nutrition, sold online and through marketplaces |
| Latest FY revenue | ₹338 crore (FY25), up 43.2% from ₹236 crore (FY24) — RoC filings via Entrackr |
| Latest FY profit/loss | Net loss of about ₹23 crore (FY25; Inc42 reports ₹22.5 crore), after a net profit of about ₹8.6 crore (FY24) |
| Listed | Private (not listed as of September 2026) |
| Last valuation | Reported at about $135 million (roughly ₹1,300 crore) per Tracxn/PitchBook estimates; company has not confirmed a figure |
| Key backers / CEO | Xponentia Capital (2024), Fireside Ventures, Kae Capital, Whiteboard Capital; CEO Mansuk Lala |
What Traya does
Traya sells treatment for hair loss to Indian adults, mostly men with male-pattern baldness (androgenic alopecia) and women with diffuse thinning, and it does so as a health service rather than a beauty purchase. A customer takes an online hair test covering lifestyle, stress, diet, gut health and hormones; a doctor reviews the inputs; and the customer receives a personalised five-to-six-month regimen — typically a mix of Ayurvedic formulations, dermatological actives and nutritional supplements — plus an assigned “hair coach” who follows up to keep them on the plan. The pitch is that hair fall usually has an internal root cause, so a single product cannot fix it. What Traya is really selling is adherence to a course, not a bottle on a shelf.
The origin
The founding insight came from failure, not a market study. Altaf Saiyed, a biomedical engineer, was in his late twenties and running hard at a startup when his health unravelled — thyroid trouble, rising uric acid, weight gain and rapid hair loss. He tried the obvious routes one at a time. Dermatology alone did not hold. Ayurveda alone did not hold. What worked, he and his co-founder Saloni Anand later described, was combining both with a corrected diet, so the scalp treatment, the internal balance and the nutritional gaps were addressed together rather than in isolation.
That personal fix became the product thesis: treat hair loss the way a clinic would treat a chronic condition, by looking at the whole body and holding the patient to a plan. Anand, an engineer-turned-marketer, and Saiyed built Traya around that idea in 2019 and later brought in pharma veteran Mansuk Lala to run the company as CEO. The early proof was tiny and hands-on — the founders personally coached the first cohort of roughly 55 customers, of whom 36 showed visible improvement by month five, a pilot result the company still cites.
The struggle years
Traya spent its first years fighting two things at once: a category that did not believe hair fall was medical, and its own economics. Convincing a customer to buy a six-month regimen — and to keep taking it — is far harder than selling a shampoo on impulse, and the cost of that persuasion showed up directly in the accounts.
- The category is education-heavy: because buyers must be taught that hair loss has internal causes, customer-acquisition cost stays high and marketing spend cannot easily be cut without starving the funnel (Outlook Business, 2025).
- FY23 was deeply loss-making: revenue was just ₹61 crore and the net loss was about ₹28 crore, with marketing and sales alone at roughly ₹51 crore — nearly as large as total revenue (RoC filings via Entrackr).
- Funding came in fits and starts. After a $2.2 million (about ₹16 crore) pre-Series A in January 2022, Traya went roughly two years without a new equity round before raising again in April 2024 (Entrackr; IndianWeb2).
- Retention is the whole game, and it is fragile — a five-to-six-month course means revenue depends on customers not quitting halfway, so drop-off directly erodes the model.
The turning point
The turning point was FY24, when the model finally worked at scale. Revenue jumped 3.8 times, from ₹61 crore in FY23 to ₹236 crore in FY24, and the company crossed from a ₹28 crore loss into a net profit of about ₹8.6 crore. It was a rare thing for a D2C brand: profitable growth, not growth bought with someone else’s money.
The numbers on either side of that line tell the story. In FY24 the company spent about ₹0.97 to earn each rupee of operating revenue — just inside profitability — and reported an EBITDA margin of 5.04% and a return on capital employed (ROCE) of 8.7%, ending the year with roughly ₹85 crore of cash against about ₹159 crore of current assets. Marketing and sales rose to about ₹98 crore in FY24 but, crucially, fell as a share of the business — the spend was now buying profitable revenue rather than chasing it. That single year is what turned Traya from a promising loss-maker into a company investors would price in the hundreds of crores.
The money behind it
Traya has raised modestly by D2C standards — Tracxn and Clay put total funding at about $18.7 million across five rounds — and has leaned on capital efficiency rather than mega-rounds.
- Pre-Series A — $2.2 million (about ₹16 crore), January 2022: led by Fireside Ventures, with Kae Capital and Whiteboard Capital participating (IndianWeb2; Entrackr).
- Latest round — ₹75 crore from Xponentia Capital, 2 April 2024: the company’s first fresh capital in roughly two years, described by Traya as a step toward taking its “clinically proven hair growth treatment to the masses” (Entrackr; Outlook Business).
- Named backers over time: Fireside Ventures, Kae Capital, Whiteboard Capital and Xponentia Capital, with venture-debt and other investors listed in aggregator databases (Tracxn; Clay).
- Valuation: reported at roughly $135 million (about ₹1,300 crore) by Tracxn and PitchBook estimates; Traya has not publicly confirmed a valuation, so this figure should be read as reported, not audited.
What each backer changed is less about headline size than signal: Fireside Ventures, a consumer-brand specialist, gave the young brand category credibility in 2022; Xponentia’s 2024 cheque arrived after profitability, funding a shift from pure online selling toward wider distribution.
How it makes money
Traya earns almost entirely from selling its treatment kits, but the mechanics are closer to a subscription than a one-off sale.
- Money in: product sales made up 99.36% of total operating revenue in FY24 — this is a product business, not a consultation-fee business (RoC filings via Entrackr).
- The plan, not the product: customers buy a five-to-six-month regimen, so a single acquired customer generates several months of repeat orders, giving the revenue a recurring shape.
- Costs out — three big buckets in FY25: sales and marketing about ₹138 crore, cost of materials about ₹83 crore, and employee benefits about ₹83 crore (RoC filings via Entrackr).
- Where the margin sits: the swing factor is marketing efficiency. In FY24 the company spent about ₹0.97 to earn each rupee of operating revenue and made money; in FY25 that rose to about ₹1.08, and it lost money.
- The part people get wrong: Traya is not primarily a “clinic” earning consultation fees — doctor review and coaching are the retention engine that makes the product sales repeat, not a separate revenue line.
- Channels: selling is led by Traya’s own app and website, supported by marketplaces including Amazon and Flipkart (Entrackr).
The numbers
Three years of RoC-filed figures (as reported by Entrackr and Inc42), in ₹ crore:
| Metric (₹ crore) | FY23 | FY24 | FY25 |
| Revenue from operations | 61 | 236 | 338 |
| Net profit / (loss) | (28) | ~9 | (23) |
| Total expenses | ~89 | 229 | 366 |
| Sales & marketing | ~51 | ~98 | ~138 |
| Employee benefits | ~9 | ~36 | ~83 |
| Cost of materials | ~15 | ~54 | ~83 |
- Revenue growth: 3.8x in FY24, then 43.2% in FY25 — still fast, but a sharp deceleration from the prior year.
- Profitability round-trip: from a ₹28 crore loss (FY23) to a ~₹9 crore profit (FY24) and back to a ~₹23 crore loss (FY25).
- The FY25 reversal was cost-driven: employee benefits rose about 130% and sales and marketing about 40% year on year, outpacing the 43.2% revenue gain (Entrackr).
- Margins flipped with it: EBITDA margin moved from +5.04% (FY24) to −6.18% (FY25); ROCE from +8.7% to −20.47% (Entrackr).
Where the money comes from
The revenue mix is unusually concentrated, and that concentration is both the strength and the surprise.
- One category: hair health accounts for essentially the entire business, with product sales at 99.36% of operating revenue (FY24) — there is little diversification to cushion a bad quarter.
- Online-first: Traya grew as a digital-first D2C brand selling through its own app and site plus Amazon and Flipkart, rather than through a retail footprint (Entrackr; Outlook Business).
- The surprise — customers, not shelf space: at its April 2024 round Traya said it had served over 10 lakh (about 1 million) customers, a company-stated figure; earlier coverage cited about 2.5 lakh customers in 2022–23 (The Better India), and aggregator estimates put the active user base lower, around 4.5 lakh (VFS/Tracxn). The gap between cumulative and active users matters for a course-based model.
- People-heavy for a product brand: the company reported growing to over 800 employees by 2025 (Tracxn lists around 761), reflecting the coaching and doctor-review layer built into the product.
The risks
- Marketing dependence and CAC. Sales and marketing was about ₹138 crore in FY25 — roughly 41% of revenue. Because the category needs constant consumer education, cutting spend risks starving the funnel, but sustaining it is exactly what pushed FY25 into loss. Profit is hostage to ad efficiency.
- Single-category concentration. With about 99% of revenue from hair products, any slowdown in that one category, a shift in customer sentiment, or a stronger competitor hits the whole business at once. There is no second engine.
- Regulatory and efficacy-claim exposure. Traya’s plans span supplements, Ayurveda and dermatological actives; some hair-loss actives such as minoxidil and finasteride are regulated drugs, and health-outcome marketing draws scrutiny from advertising and drug regulators. Aggressive efficacy claims are a standing compliance risk for the whole doctor-led-D2C model.
- Well-funded competition. Traya competes with larger consumer-health players and rivals such as Mosaic Wellness (Man Matters) and other D2C hair brands, several with deeper marketing budgets, in a market where switching costs for customers are low.
The takeaway
Traya’s real innovation was not a molecule; it was reframing a commodity. Shampoo is bought on impulse and priced like a commodity, so margins are thin and loyalty is thinner. By turning hair loss into a diagnosed condition with a multi-month plan and a coach, Traya converted a one-time purchase into a course with repeat revenue and stickiness. The transferable lesson is sharper than “sell subscriptions”: a recurring model only pays if the cost of acquiring and keeping each customer stays below what that customer is worth over the plan. FY24 proved the model can clear that bar; FY25 showed how quickly a decision to buy growth — through marketing and headcount — can drag it back below the line, even while the top line still grows. Durable is the version that holds the discipline in both years.
Frequently asked questions
What does Traya actually sell?
A doctor-reviewed, personalised hair-loss treatment plan lasting five to six months, combining Ayurveda, dermatology and nutrition, sold as a kit with follow-up coaching rather than as a single product. Product sales made up 99.36% of its operating revenue in FY24.
Is Traya profitable?
It was in FY24, with a net profit of about ₹9 crore on ₹236 crore of revenue. In FY25 it slipped back to a net loss of about ₹23 crore on ₹338 crore of revenue, as marketing and employee costs rose faster than sales (RoC filings via Entrackr and Inc42).
Who founded Traya and who runs it?
Traya was co-founded in 2019 by Saloni Anand and Altaf Saiyed, a married couple, after Altaf’s own experience with hair loss. Pharma-industry veteran Mansuk Lala is the CEO and is listed as a co-founder in company databases.
How much money has Traya raised, and from whom?
About $18.7 million in total (Tracxn/Clay), including a $2.2 million pre-Series A in January 2022 led by Fireside Ventures with Kae Capital and Whiteboard Capital, and ₹75 crore from Xponentia Capital in April 2024. Its valuation is reported at roughly $135 million but is not company-confirmed.
Did Traya appear on Shark Tank India?
We found no public record of Traya pitching on, or securing a deal from, Shark Tank India as of September 2026. Its outside capital came from venture and private-equity rounds listed in the Sources. If you have seen a claim otherwise, treat it as unverified until a primary source confirms it.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr — “Traya returns to losses in FY25 as marketing and employee costs surge” (September 2026)
- Entrackr — “Traya posts Rs 236 Cr revenue in FY24; turns profitable” (2024)
- Entrackr — “Traya secures Rs 75 Cr from Xponentia Capital” (April 2024)
- Inc42 — “Traya Slips Into The Red In FY25, Posts INR 22.5 Cr Loss” (2026)
- Outlook Business — “How Traya Uses AI and Clinical Rigor to Fix India’s Hair Loss Problem” (2025)
- The Better India — “‘My Husband’s Hairfall Inspired These Hair Solutions'” (2023)
- IndianWeb2 — “HealthTech Startup Traya Raises $2.2 Mn in Pre-series A” (January 2022)
- Tracxn — Traya / Tatvartha Health Private Limited company and funding profile (2026)
- Clay — Traya Health funding and investors (2026)
- ZaubaCorp — Tatvartha Health Private Limited, CIN U85300GJ2019PTC107353 (incorporation and registration details)
- PitchBook — Traya company profile: valuation, funding and investors (2026)
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.